Form 8-K

8-K — Zeo ScientifiX, Inc.

Accession: 0001829126-26-003301

Filed: 2026-04-09

Period: 2026-04-09

CIK: 0001557376

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — zeoscientifix_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (zeoscientifix_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: zeoscientifix_8k.htm · Sequence: 1

false

0001557376

2026-04-09

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): April 9, 2026

ZEO SCIENTIFIX, INC.

(Exact name of registrant as specified in its charter)

Nevada

000-55008

47-4180540

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

3321 College Avenue, Suite 246

Davie, Florida

33314

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (888) 963-7881

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class

Trading Symbol

Name of each exchange on which registered

None

N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

As used in this Current Report on Form 8-K (this

“Report”), and unless otherwise indicated, the terms “the Company,” “ZEO,” “we,”

“us” and “our” refer to Zeo ScientifiX, Inc.

Item 8.01 Other Events.

On April 9, 2026, ZEO issued a press release announcing

that ZEO had entered into to a memorandum of understanding (‘MOU”) with Regen Therapy for the establishment of an exclusive

scientific and biologics strategic collaboration, pursuant to which ZEO is expected to be positioned as the core supplier of advanced

biologic therapeutics to be incorporated into the next-generation regenerative offerings on Regen’s clinical platform.

A copy of the press release is included as Exhibit

99.1 to this Report.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit No.

Description

99.1

Press Release, dated April 9, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 9, 2026

ZEO SCIENTIFIX, INC.

By:

/s/ Ian T. Bothwell

Ian T. Bothwell

Chief Executive Officer and Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: zeoscientifix_ex99-1.htm · Sequence: 2

Exhibit 99.1

FOR

IMMEDIATE RELEASE

Regen

Therapy Partners with Stealth Health to Bring Specialized

Telemedicine Services and Longevity Programs to 3,000 Clinics—Powered by an

Exclusive

Scientific and Biologics Strategic Collaboration with ZEO ScientifiX (OTCQB: ZEOX)

Regen

Therapy’s 24,000-practitioner network will unlock a fully integrated care ecosystem—featuring Stealth Health’s licensed

prescriber team and specialized therapies, Metabolic Code®-driven longevity programs and ZEO ScientifiX’s

advanced biologic offerings—delivered through a white-label telemedicine platform embedded directly into clinical practice.

DAVIE,

FL – April 9, 2026 – ZEO ScientifiX, Inc. (OTCQB:

ZEOX) (“ZEO” or the “Company”), a clinical-stage biotechnology company, today announced it has entered

into a memorandum of understanding (“MOU”) with Regen Therapy, for the establishment of an exclusive scientific and

biologics strategic collaboration, pursuant to which ZEO is positioned as the core supplier of advanced biologic therapeutics underpinning

the next-generation of regenerative product offerings on Regen Therapy’s platform. In parallel, Regen Therapy has entered into

a strategic partnership with Stealth Health to bring scalable, white-label telemedicine and longevity services to its network

of more than 3,000 clinics and 24,000 practitioners across the U.S. Together, these collaborations create a vertically integrated ecosystem—combining

clinical delivery, telemedicine infrastructure, and scientifically advanced biologic product development—to enable clinics to deliver

comprehensive, data-driven longevity and regenerative care at scale.

The

collaboration with Stealth Health will enable participating clinics to integrate a licensed prescriber network, pharmacy fulfillment

infrastructure, and telemedicine platform directly into their existing operations—allowing them to offer physician-guided consultations,

compounded medications, hormone replacement therapy, GLP-1 weight management programs, therapeutic peptides, and broader longevity protocols

without building in-house capabilities.

“Regen

Therapy has built one of the most clinically credible networks in regenerative medicine, and the clinics in their ecosystem are hungry

for ways to serve their patients better,” said Matthew Mazzuca, CEO and Co-Founder of Stealth Health. “Our platform

gives those clinics instant access to our prescriber network, our pharmacy fulfillment infrastructure, and a full menu of longevity-focused

services their patients are already asking for—all delivered under the clinic’s own brand. This is how longevity medicine

scales: by empowering the clinics that are already on the front lines.”

Complementing

this infrastructure, the MOU contemplates that ZEO ScientifiX will serve as Regen Therapy’s exclusive partner for biologic research,

development, and manufacturing of biologic therapeutics to be incorporated into Regen’s platform. ZEO’s expertise in extracellular

vesicle biology, perinatal-derived therapeutics, and acellular signaling technologies will support the development and supply of advanced

regenerative products incorporated into Regen’s expanding clinical platform. This relationship reflects Regen’s commitment

to scientific rigor, product innovation, and scalable clinical outcomes.

“For

ZEO ScientifiX, the strategic collaboration represents both validation of its commitment to research and product development and an opportunity

to play a central role in a rapidly expanding clinical network expected to be a major force in the U.S. regenerative medicine market.”

said Ian Bothwell, Chief Executive Officer of ZEO ScientifiX. “By

aligning with Regen Therapy’s platform, we believe ZEO’s innovative therapeutics can be translated more efficiently into

real-world clinical applications.”

Positioned

as an extension of brick-and-mortar care, the model allows clinics to expand into high-demand, specialized services while Stealth Health

manages clinical oversight, prescription workflows, and fulfillment, and ZEO ensures consistent, high-quality biologic product availability

through cGMP-compliant processes. The turnkey approach removes regulatory and operational barriers while introducing a new level of scientific

depth to clinical offerings.

Central to the platform is integration with the

Metabolic Code® system, a precision health platform founded by James LaValle, RPh, CCN. Utilizing a proprietary

40,000-point Bayesian model, the platform delivers individualized health assessments and care plans by identifying imbalances across five

key physiological networks, known as TRIADS™. The system, already adopted by organizations including LIFE TIME, enables clinics

to introduce data-driven longevity programming as part of a fully managed patient experience.

“The

future of longevity medicine is personalized, data-driven, and accessible—and it starts inside the clinic,” said James

LaValle, clinical pharmacist, Founder of Metabolic Code®, Co-Chair of the American Academy of Anti-Aging Medicine,

Chair of the International Peptide Society, and Chief Science Officer at LIFE TIME. “When you combine the clinical depth of Metabolic

Code’s assessment platform with Regen Therapy’s clinic network and Stealth Health’s prescriber infrastructure, you

give practitioners the ability to deliver precision longevity care to their patients at a scale that hasn’t been possible until

now.”

“What we are seeking to build is not a single

therapy, but a new clinical architecture for how regenerative medicine is delivered,” said George C. Shapiro, MD, FACC, Chief

Medical Officer of ZEO ScientifiX. “By integrating biologic engineering, cGMP manufacturing, and data-driven clinical deployment,

this strategic collaboration provides the potential to establish the foundation for a scalable system—one capable of ultimately

standardizing outcomes across a national network and fundamentally advancing how we treat aging, inflammation, and cellular dysfunction.”

“This

is not just a partnership, it’s the creation of an integrated ecosystem designed to define the future of longevity and regenerative

health,” Sanjiv Lal, partner at Regen Therapy.

The

partnership comes as demand for proactive, personalized health solutions continues to accelerate, with the global longevity market projected

to exceed $93 billion by 2027. Despite this growth, many clinics remain limited by lack of access to specialized prescribers, pharmacy

networks, and integrated technology. By combining Regen Therapy’s clinical network and education platform with Stealth Health’s

infrastructure and Metabolic Code’s analytics engine, the partnership creates a scalable pathway for providers to expand offerings,

drive new revenue, and meet evolving patient expectations.

About

Regen Therapy

Regen

Therapy is a clinical education and consulting platform for healthcare providers and longevity clinics. Co-founded by Dr. Arvind Chakravarthy,

MD, MBA, and Sanjiv Lal, Regen Therapy provides research insights, clinical education, fractional longevity advisory services, and operational

support to help medical practices implement regenerative medicine programs responsibly and at scale. With partnerships spanning organizations

including Hall of Fame Health and a growing network of over 3,000 clinics, Regen Therapy is defining the future of regenerative science.

About

Stealth Health

Stealth

Health is a telemedicine and longevity medicine company headquartered in Texas. The company provides a white-label MSO platform for clinic

partners, a licensed prescriber network, direct-to-patient telehealth services, and pharmacy fulfillment coordination—all built

on a HIPAA-compliant technology stack. Stealth Health’s platform enables brick-and-mortar clinics to offer their patients specialized

medications, hormone therapies, peptides, and longevity programs under the clinic’s own brand.

About

ZEO ScientifiX

ZEO

ScientifiX (OTCQB: ZEOX) is a clinical-stage biopharmaceutical company specializing in the development and cGMP-compliant manufacturing

of advanced biologic therapeutics. The company is focused on advancing regenerative medicine through scientific innovation, rigorous

research, and scalable product development, supporting next-generation therapies in longevity and human performance.

About

Metabolic Code®

Metabolic

Code® is a cloud-based precision health platform founded by Jim LaValle, RPh, CCN, that uses a proprietary 40,000-point

Bayesian Model algorithm to deliver personalized health assessments, targeted care plans, and ongoing metabolic optimization.

Forward-Looking

Statements Certain statements contained in this press release should be considered forward-looking statements within the meaning

of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform

Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties. Although Regen Therapy, Zeo Scientifix,

Stealth Health and Metaboloc Code all believe that the expectations reflected in these forward-looking statements are reasonable, they

do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Actual results could vary dramatically.

Regen Therapy, Zeo Scientifix, Stealth Health and Metaboloc Code have no intention and specifically disclaims any duty to update the

information in this press release.

Media Contacts

Stealth

Health

press@stealth.health

stealth.health

Regen

Therapy

info@regentherapy.com

regentherapy.com

Metabolic

Code

TeamLaVallePR@HillTop-Ent.com

TeamLaVallePR@BehrmanCesa.com

Zeo

Scientifix, Inc.

ir@zeoscientifix.com

###

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Apr. 09, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 09, 2026

Entity File Number

000-55008

Entity Registrant Name

ZEO SCIENTIFIX, INC.

Entity Central Index Key

0001557376

Entity Tax Identification Number

47-4180540

Entity Incorporation, State or Country Code

Entity Address, Address Line One

3321 College Avenue

Entity Address, Address Line Two

Suite 246

Entity Address, City or Town

Davie

Entity Address, State or Province

Entity Address, Postal Zip Code

33314

City Area Code

(888)

Local Phone Number

963-7881

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration